Archive — US — techcrunch
Vijay Pande, founding partner of a16z bio and health strategy, steps down
Vijay Pande, founding partner of a16z Bio + Health, is stepping down after leading the division since 2014, which raised nearly $3 billion. The firm seeks a $750 million fifth fund, despite recent announcements about a $500 million biotech fund with Eli Lilly. Pande's notable investments include Devoted Health and Freenome, and he previously worked at Stanford University.
Key points
- Vijay Pande announced his departure from a16z Bio + Health.
- a16z Bio + Health was founded in 2014 and raised four funds close to $3 billion.
- The fifth fund being sought is significantly smaller at $750 million.
- In January, a16z Bio + Health announced a $500 million biotech fund backed by Eli Lilly.
- Pande's notable investments include companies focused on personalized health and cancer detection.
- Before a16z, he was a professor at Stanford University.
Why it matters
- The exit of a key figure like Pande may impact investor confidence in a16z Bio + Health.
- The current trend towards personalized health and the integration of AI in healthcare reflects ongoing developments in the biotech industry.
- Venture capital interest in healthcare has surged, influenced by the pandemic and technological advances.
- Pande's departure may signify a shift in investment strategy as the demand for health tech grows.
Vijay Pande stepping down marks a pivotal moment for a16z Bio + Health, potentially reshaping the firm's strategy in a rapidly evolving biotech landscape while highlighting the significance of personalization and AI integration in healthcare.